Dornase alfa

Drug Profile

Dornase alfa

Alternative Names: DNase; Dornase alpha; dornase-alpha; Pulmozyme; Recombinant human deoxyribonuclease I; rhDNase

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; University of Illinois at Chicago
  • Class Antifibrotics; Recombinant proteins
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase I/II Dry eyes; Graft-versus-host disease
  • Discontinued Chronic obstructive pulmonary disease; Lupus nephritis

Most Recent Events

  • 06 Feb 2017 Dornase alfa is still in phase I/II trials for Dry eyes in USA (Ophthalmic, drops)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Jul 2014 Phase-I/II clinical trials in Dry eyes in USA (Ophthalmic, drops) (NCT02193490)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top